Skip to search boxSkip to navigationSkip to main content

Elevated plasma transforming growth factor-β1 levels in breast cancer patients decrease after surgical removal of the tumor

  • F. M. Kong
    ,
  • M. S. Anscher
    ,
  • T. Murase
    ,
  • B. D. Abbott
    ,
  • J. D. Iglehart
    ,
  • R. L. Jirtle(corresponding author)
*Corresponding author for this work
  • Duke University
Scholary Output:
Contribution to journal
Article
Research
Peer-review

Sustainable Development Goals

  • SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well

Abstract

<p>Objective: The authors determined whether untreated breast cancer patients have elevated plasma levels of transforming growth factor-β<sub>1</sub> (TGF-β<sub>1</sub>). Summary Background Data: Increased plasma TGF-β<sub>1</sub> levels recently were found after chemotherapy in patients with advanced breast cancer. However, it currently is unknown whether this elevation in plasma TGF-β<sub>1</sub> is caused by chemotherapy-induced normal tissue damage or whether it results from the presence of the tumor. Methods: An enzyme-linked immunosorbent assay was used to measure plasma TGF-β<sub>1</sub> levels in 26 newly diagnosed breast cancer patients before and after definitive surgery. Patients were grouped by postoperative tumor status: 1) negative lymph nodes (group 1); 2) positive lymph nodes (group 2); and 3) overt residual disease (group 3). The site of TGF-β<sub>1</sub> production in the tumors was localized by immunohistochemistry and in situ hybridization. Results: Plasma TGF-β<sub>1</sub> levels were elevated preoperatively in 81% of the patients; TGF-β<sub>2</sub> and TGF-β<sub>3</sub> were undetectable. The preoperative TGF-β<sub>1</sub> levels in the three patient groups were similar; however, the postoperative plasma TGF-β<sub>1</sub> levels differed by disease status. The mean plasma TGF-β<sub>1</sub> level in group 1 (n = 12) normalized after surgery (19.3 ± 3.2 vs. 5.5 ± 1.0 ng/mL, p < 0.081). In contrast, the mean plasma TGF-β<sub>1</sub> levels remained above normal in both group 2 (n = 9) and group 3 (n = 5) after surgery. Transforming growth factor-β<sub>1</sub> expression was found to be preferentially increased in the tumor stroma. Conclusions: Breast tumors result in increased plasma TGF-β<sub>1</sub> levels in 81% of patients. After surgical removal of the primary tumor, the plasma TGF-β<sub>1</sub> level normalizes in the majority of patients; persistently elevated levels correlate with the presence of lymph node metastases or overt residual tumor. These findings suggest that the usefulness of TGF-β<sub>1</sub> as a potential plasma marker for breast tumors deserves further study.</p>

Publication Information

Output type

Scholary Output:
Contribution to journal
Article
Research
Peer-review

Original language

English (US)

Pages from-to (Number of pages)

Pages 155-162 (8 pages)

Journal (Volume, Issue Number)

Annals of surgery (Volume 222, Issue 2)

Publication milestones

  • Published - 1995

Publication status

Published - 1995

ISSN

0003-4932

Publication IDs

  • Scopus: 0029133133
  • PubMed: 7543740

Publication metrics

Metrics

Scopus
citations
Fractional count
1
Fractional count
0.17
Fractional count
5
Fractional count
0.83
Fractional count
1
Fractional count
1

PlumX, opens in new tab

Citation count
189
Captures
48